## FOR 24 HOUR REGISTRATION - ALL FIELDS MUST BE COMPLETED

## **PATIENT** Registration

Form Completed By: 

Doctor

GenCA N  $\square$  Pharmacist



Phone 1-866-501-3338 Fax 1-800-497-9592 Wehsite www.aencan.ca

Local Case Coord	ainator/Case Manager Gen-Clozapine ACCESS Network VVCUSILE WWW.YCIICUII.Cl
Please check one.	☐ Modification ☐ Discharged from Hospital
☐ Continuing Treatment Patient**  (Patient is currently receiving another brand of Clozapine.)	☐ Transferred to another brand of Clozapine ☐ Discontinued treatment with Clozapine Date / / DD/Mon/YYY
☐ New Patient Enrollment	<del></del>
	Reason for Discontinuation
SECTION 1. Patient Information	
If patient previously enrolled, please indicate  GenCAN number:	Status: □ Inpatient □ Outpatient
Patient   Prov.:   Prov. Health Ins. #:	Gender: □ Male □ Female
Date of Birth:/	e: $\square$ Caucasian $\square$ Black $\square$ Asian $\square$ Other (specify):
Baseline blood result: WBC Result: ANC Result For Continuing Treatment Patient only**:	t:/
Start Date on Clozapine:/DD/Mon/YYYY (Any Brand)	✓ Monitoring Frequency: □ Weekly □ Every 2 weeks □ Every 4 weeks
SECTION 2. Laboratory and Local Case Coordinator/Ma	nager
Laboratory: Tel.: ( )	) Fax.: ( )
Case Manager: Tel.: (	
Pharmacy Name:  Address:	
	·
Wholesaler: Account #: _	
I confirm that all dispensing pharmacists at this location will only dispense has had his/her blood drawn for a Complete Blood Count and Differential (	e Gen-Clozapine on a weekly, two-weekly or monthly basis upon confirmation that the patien CBC and Diff.) for the current period.
Pharmacist Signature:	
<b>SECTION 4.</b> To be completed and signed by Treating <b>Ph</b>	nysician → □ Lab Req. CC to GENCAN 1-800-497-9592
Physician Name: Prov. Lice	ense No.: Language: 🗆 English 🗆 French
Patient Treatment Location:	■ Baseline CBC & Diff. complete
Address:	City:
specified frequency. I understand that no pharmacy will dispense any brand of clozapin way I will be able to inform the laboratory to send my patient's results to the appropriate patient has been verified. I have informed the patient and he/she has not objected and, in fact, has consented to ti	rential) for this patient (identified above) as required by the clozapine Product Monographs is performed at a tent of the tent without my prior knowledge and permission regarding which brand is being dispensed. In the manufacturer's clozapine database. I will not prescribe clozapine until the nonrechallengeable status of the release of relevant personal information and safety information held within a clozapine database to any the safe utilization of this medication and/or for the continuous monitoring of the patient. The safety information the safe utilization of this medication and/or for the continuous monitoring of the patient.

which may be released includes, the non-rechallengeable/hematologic status of the patient, white blood cell counts and absolute neutrophils counts, dates and other information as may be relevant to the safe treatment of the patient with clozapine. Additional relevant personal information which may be released includes patient initials, date of birth, gender, province and health care number.

I have also informed the patient of the existence of the GenCAN Privacy Policy which they may view at www.gencan.ca. In addition, they may contact Genpharm's Privacy Officer directly with questions.

\_ DD/Mon/YYYY Physician Signature: Date:\_\_\_